Alyson Maeve Curry

Ms. Alyson Maeve Curry


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CMCarol Milligan
Carol Milligan
DCDale Cowley
Dale Cowley
WSWilliam Stewart
William Stewart
ACAlyson Maeve Curry
Alyson Maeve Curry
EFElizabeth Forbes
Elizabeth Forbes
GHGregory Hawkins
Gregory Hawkins
Background/Objectives: Charcot first described ALS in 1869, but the specific mechanisms that mediate the disease pathology are still not clear. Intense research efforts have provided insight into unique neuroanatomical regions, specific neuronal populations and genetic associations for ALS and other neurodegenerative diseases; however, the experimental results also suggest a convergence of these events to common toxic pathways. We propose that common toxic pathways can be therapeutically targeted, and this intervention will be effective in slowing progression and improving patient quality of life. Here, we focus on understanding the role of IL6 trans-signaling in ALS disease processes. Methods: We leveraged unique mouse models of IL6 trans-signaling that we developed that recapitulate the production of active sIL6R in a genotypic and quantitative fashion observed in humans. Given that the SOD1 transgenic mouse is one of the most highly studied and characterized models of ALS, we bred SOD1G93A mice with IL6R trans-signaling mice to determine how enhanced trans-signaling influenced symptom onset and pathological processes, including neuromuscular junction (NMJ) denervation, glial activation and motoneuron (MN) survival. Results: The results indicate that in animals with enhanced trans-signaling, symptom onset and pathological processes were accelerated, suggesting a role in disease modification. Administration of an IL6R functional blocking antibody failed to alter accelerated symptom onset and disease progression. Conclusions: Future work to investigate the site-specific influence of enhanced IL6 trans-signaling and the tissue-specific bioavailability of potential therapeutics will be necessary to identify targets for precise therapeutic interventions that may limit disease progression in the 60% of ALS patients who inherit the common Il6R Asp358Ala variant.

23 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ACAlyson Maeve Curry
Alyson Maeve Curry
KHKatherine M Holleran
Katherine M Holleran
SJSara R Jones
Sara R Jones
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by molecular pathologies, the accumulation of amyloid‐β and neurofibrillary tau, and deficits in memory and cognition. Neuropsychiatric symptoms (NPS), such as depression and apathy, are increasingly viewed as early manifestations of AD and have been linked to disease development and progression. Dopamine, a critical regulator of motivation, learning, and memory, has been implicated in AD pathophysiology, but its specific role in disease progression remains underexplored. This study investigates the relationship between cognitive deficits and mesolimbic dopamine function in Tau P301S mice, a model of tauopathy. Method: Cognitive and behavioral assessments were conducted in male and female Tau P301S mice at 3, 6, and 9 months of age using novel object recognition (NOR), social interaction, and sucrose preference tests. Mesolimbic dopamine function was evaluated through ex vivo fast‐scan cyclic voltammetry in the nucleus accumbens core. Result: Cognitive deficits were evident as early as 3 months in Tau P301S mice. By 6 months, these mice exhibited impaired NOR performance and reduced sucrose preference. Although dopamine release and reuptake remained unchanged at this stage, there was reduced D2 receptor sensitivity that correlated with cognitive deficits. At 9 months, Tau P301S mice demonstrated worsened behavioral and cognitive impairments, accompanied by trending reductions in dopamine release and reuptake, as well as further declines in D2 receptor sensitivity. Notably, increased NOR performance positively correlated with dopamine release. A small cohort of APP/PS1 mice displayed similar deficits in behavior and dopamine function. Conclusion: Tau P301S mice exhibit progressive cognitive and social impairments that correlate with alterations in mesolimbic dopamine function. Similar dysfunctions were observed in APP/PS1 mice, underscoring the relevance of dopamine dysregulation across multiple AD models. These findings highlight the role of mesolimbic dopamine system dysfunction in AD and suggest targeting dopamine‐related pathways to alleviate cognitive and behavioral deficits.